Pennsylvania Trust Co Buys 9,382 Shares of Johnson & Johnson (JNJ)

Pennsylvania Trust Co grew its stake in shares of Johnson & Johnson (NYSE:JNJ) by 2.3% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 412,199 shares of the company’s stock after acquiring an additional 9,382 shares during the period. Johnson & Johnson accounts for 2.2% of Pennsylvania Trust Co’s investment portfolio, making the stock its 4th biggest holding. Pennsylvania Trust Co’s holdings in Johnson & Johnson were worth $50,017,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Nicollet Investment Management Inc. bought a new stake in Johnson & Johnson in the fourth quarter worth $2,897,000. Teacher Retirement System of Texas boosted its holdings in Johnson & Johnson by 12.4% in the fourth quarter. Teacher Retirement System of Texas now owns 2,141,372 shares of the company’s stock worth $299,192,000 after purchasing an additional 236,340 shares in the last quarter. MPI Investment Management Inc. bought a new stake in Johnson & Johnson in the fourth quarter worth $1,829,000. Anchor Capital Advisors LLC boosted its holdings in Johnson & Johnson by 1.0% in the fourth quarter. Anchor Capital Advisors LLC now owns 197,400 shares of the company’s stock worth $27,581,000 after purchasing an additional 1,914 shares in the last quarter. Finally, Dubuque Bank & Trust Co. boosted its holdings in Johnson & Johnson by 23.6% in the fourth quarter. Dubuque Bank & Trust Co. now owns 107,827 shares of the company’s stock worth $15,065,000 after purchasing an additional 20,584 shares in the last quarter. Institutional investors and hedge funds own 66.67% of the company’s stock.

Shares of JNJ opened at $139.39 on Tuesday. The stock has a market cap of $370.70 billion, a PE ratio of 19.09, a P/E/G ratio of 2.19 and a beta of 0.70. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.65 and a quick ratio of 1.33. Johnson & Johnson has a 52 week low of $118.62 and a 52 week high of $148.32.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, July 17th. The company reported $2.10 EPS for the quarter, beating the Zacks’ consensus estimate of $2.06 by $0.04. Johnson & Johnson had a net margin of 1.70% and a return on equity of 32.79%. The business had revenue of $20.83 billion during the quarter, compared to analyst estimates of $20.39 billion. During the same quarter in the prior year, the business earned $1.83 earnings per share. The firm’s revenue for the quarter was up 10.6% on a year-over-year basis. Equities analysts predict that Johnson & Johnson will post 8.14 EPS for the current year.

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 11th. Investors of record on Tuesday, August 28th were given a $0.90 dividend. This represents a $3.60 annualized dividend and a yield of 2.58%. The ex-dividend date of this dividend was Monday, August 27th. Johnson & Johnson’s dividend payout ratio (DPR) is presently 49.32%.

A number of brokerages recently issued reports on JNJ. ValuEngine upgraded shares of Johnson & Johnson from a “sell” rating to a “hold” rating in a report on Saturday, July 28th. Sanford C. Bernstein began coverage on shares of Johnson & Johnson in a report on Wednesday, June 27th. They issued a “market perform” rating and a $129.00 price objective for the company. Credit Suisse Group set a $151.00 price objective on shares of Johnson & Johnson and gave the stock a “buy” rating in a report on Tuesday, June 12th. Jefferies Financial Group set a $145.00 target price on shares of Johnson & Johnson and gave the stock a “buy” rating in a research report on Sunday, July 15th. Finally, Goldman Sachs Group raised shares of Johnson & Johnson from a “sell” rating to a “neutral” rating in a research report on Thursday, July 12th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and nine have assigned a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $143.91.

In related news, COO Michael E. Sneed sold 29,000 shares of the stock in a transaction dated Monday, August 27th. The shares were sold at an average price of $134.80, for a total value of $3,909,200.00. Following the completion of the transaction, the chief operating officer now owns 59,124 shares of the company’s stock, valued at $7,969,915.20. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CAO Ronald A. Kapusta sold 7,899 shares of the stock in a transaction dated Friday, September 7th. The stock was sold at an average price of $137.18, for a total transaction of $1,083,584.82. Following the completion of the transaction, the chief accounting officer now directly owns 25,725 shares of the company’s stock, valued at approximately $3,528,955.50. The disclosure for this sale can be found here. Corporate insiders own 0.22% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Recommended Story: Understanding Stock Ratings

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply